UK markets closed

MagForce AG (MGFRF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
4.85000.0000 (0.00%)
At close: 12:58PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close4.8500
Open4.6579
BidN/A x N/A
AskN/A x N/A
Day's range4.8500 - 4.8500
52-week range2.5888 - 6.4900
Volume2,500
Avg. volume35
Market cap118.034M
Beta (5Y monthly)2.36
PE ratio (TTM)8.14
EPS (TTM)0.5960
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • EQS Group

    Original-Research: MagForce AG (von GBC AG)

    Original-Research: MagForce AG - von GBC AG Einstufung von GBC AG zu MagForce AG Unternehmen: MagForce AG ISIN: DE000A0HGQF5 Anlass der Studie: Research Report (Anno) Empfehlung: Buy Kursziel: 11.00 EUR Kursziel auf Sicht von: 31.12.2022 Letzte Ratingänderung: Analyst: Cosmin Filker, Marcel Goldmann - Approval for prostate treatment imminent, - New treatment devices to be installed in Europe, - Strong growth and break-even expected from 2022 onwards Despite pandemic-related restrictions, MagForc

  • EQS Group

    MagForce AG Publishes Financial Results for the Year 2020 and Operative Highlights

    DGAP-News: MagForce AG / Key word(s): Annual Report30.06.2021 / 08:30 The issuer is solely responsible for the content of this announcement.MagForce AG Publishes Financial Results for the Year 2020 and Operative Highlights- Europe: High growth in treatment numbers beginning of 2020 - after severe COVID-19 impact European roll-out now picks up speed again- USA: Stage 2a of pivotal single-arm study for the focal ablation of intermediate risk prostate cancer completed - additional data support exce

  • EQS Group

    MagForce AG Supports World Brain Tumor Day and Informs about Various Patient Events to Raise Awareness for One of the Deadliest Oncological Indications

    DGAP-News: MagForce AG / Key word(s): Miscellaneous07.06.2021 / 08:30 The issuer is solely responsible for the content of this announcement.MagForce AG Supports World Brain Tumor Day and Informs about Various Patient Events to Raise Awareness for One of the Deadliest Oncological IndicationsBerlin, Germany, and Nevada, USA, June 7, 2021 - MagForce AG (Frankfurt, Scale, Xetra: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, offering the